Wang, Yi-Ting
Ashton, Nicholas J.
Servaes, Stijn
Nilsson, Johanna
Woo, Marcel S.
Pascoal, Tharick A.
Tissot, Cécile
Rahmouni, Nesrine
Therriault, Joseph
Lussier, Firoza
Chamoun, Mira
Gauthier, Serge
Brinkmalm, Ann
Zetterberg, Henrik
Blennow, Kaj
Rosa-Neto, Pedro
Benedet, Andréa L. http://orcid.org/0000-0001-8219-1741
Funding for this research was provided by:
Canadian Institutes of Health Research (MOP-11-51-31)
Article History
Received: 27 December 2023
Accepted: 6 May 2024
First Online: 28 May 2024
Declarations
:
: The TRIAD study was approved by the Montreal Neurological Institute PET Working Committee and the Douglas Mental Health University Institute Research Ethics Board. Written informed consent was obtained from all participants.
: Not applicable.
: The authors have no conflicts of interest to report related to this work. Outside the work presented in this paper, PRN provides consultancy services for Roche, Cerveau Radiopharmaceuticals, Lilly, Eisai, Pfizer, and Novo Nordisk. He also serves as a clinical trials investigator for Biogen, Novo Nordisk, and Biogen. HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and on advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for Biogen, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. JT has received consulting fees from the Neurotorium educational platform. SG is a member of the scientific advisory boards of Alzheon, AmyriAD, Eisai Canada, Enigma USA, Lilly Canada, Medesis, Okutsa Canada, Roche Canada, and TauRx. He is a member of the editorial board of JPAD and of the Neurotorium. He has given lectures under the auspices of Biogen Canada and Lundbeck Korea.